HDAC9 and lung carcinoma: For example, Romero et al. have shown that SMARCA4-deficient lung cancer cells do not respond to HDAC inhibition but in contrast are sensitive to inhibition of the demethylases KDM6A/B, even if MYC is concurrently amplified [56].